LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Inicio・Lista de Acciones・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Cerrado

SectorSalud

9.44 -3.28

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.36

Máximo

9.81

Métricas clave
By Trading Economics
Ingresos	42M 17M
Ventas	14M 169M
BPA	0.17
Margen de beneficio	10.237
Empleados	499
EBITDA	54M 48M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+63.21% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	561M 2.9B
Apertura anterior	12.72
Cierre anterior	9.44

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.925 / 7.38 Soporte y Resistencia

Amicus Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 nov 2025, 23:07 UTC

Charlas de Mercado

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 nov 2025, 22:22 UTC

Charlas de Mercado

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 nov 2025, 22:08 UTC

Charlas de Mercado

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 nov 2025, 21:57 UTC

Ganancias

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 nov 2025, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

20 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

20 nov 2025, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

20 nov 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Financial Services Roundup: Market Talk

20 nov 2025, 21:31 UTC

Ganancias

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 nov 2025, 21:23 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov 2025, 21:07 UTC

Ganancias

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:06 UTC

Ganancias

Webull 3Q Rev $156.9M >BULL

20 nov 2025, 21:06 UTC

Ganancias

Webull 3Q EPS 7c >BULL

20 nov 2025, 21:05 UTC

Ganancias

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 nov 2025, 21:04 UTC

Ganancias

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 nov 2025, 21:04 UTC

Ganancias

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 nov 2025, 21:04 UTC

Ganancias

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 nov 2025, 21:00 UTC

Ganancias

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 nov 2025, 21:00 UTC

Ganancias

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit 1Q Consumer Rev $894M

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 Guidance

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit 1Q Global Business Solutions Rev $3B

Comparación entre iguales

Cambio de precio

Amicus Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

63.21% repunte

Estimación a 12 meses

Media 15.88 USD 63.21%

Máximo 21 USD

Mínimo 11 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.925 / 7.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.